Gossamer Bio GAAP EPS of -$0.16 beats by $0.02, revenue of $9.9M beats by $5.95M

Stock Information for Gossamer Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gossamer Bio Inc.

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.